- Before
- Rebuilds every CRO’s budget in a spreadsheet, line by line, before she can say which bid is really lowest.
- Now
- Opens a like-for-like grid with every gap cited, sends the questions, applies the answers and signs the memo.
One CRO selection, from four bids to a signed award
NXL-301 is a Phase 3 atopic dermatitis study of Nexrakimab: 620 patients, 140 sites, 16 countries, 34 months. Four full-service CROs have bid, and the bid defence is in seven days. Here is what happens next, screen by screen, in the working solution.
- 01Morning · Oct 7
Four bids, and the lowest one looks obvious
Priya Raman · Clinical outsourcing leadPriya opens the bid room: 5 open sourcing events, 8 proposals in play, 13 assumption gaps still open, the NXL-301 bid defence on Oct 14. As submitted, the four bids stack up against a benchmark of $55.33M — Bluefen at $45.95M, Altamira $53.33M, Harborline $57.81M, Quillon $60.29M.
“As submitted, Bluefen looks lowest at $45.95M. Each CRO priced its own assumptions — switch to like-for-like to compare the study we asked for.”
- 02One switch
Like for like, the order changes
Priya Raman · Clinical outsourcing leadRe-priced to the RFP assumptions, Altamira is lowest at $54.92M. Bluefen climbs to $57.90M, third of four; Harborline comes down to $57.19M, Quillon to $59.84M. Each bar keeps a dotted line where it stood as submitted.
“Bluefen rises $11.95M — 9 assumption gaps, each cited to its page.”
- 03Sep 30, 18:42
Four proposals read, mapped and re-priced
The agentsThe proposal reader went through 410 pages and four workbooks: 865 budget lines and 162 stated assumptions, each with its page or row. The task mapper put 838 lines on the 15 standard tasks; Priya confirmed the 27 it was unsure of. The assumption checker found 17 gaps against the RFP assumptions sheet v2 and monitoring plan v1.2, and the benchmark analyst scaled 23 past awards to this study.
Below 85% confidence, a person confirms the line — the task mapper’s own limit.
- 04One click
Any number, back to its page
Priya Raman · Clinical outsourcing leadPriya clicks Bluefen’s site management and monitoring. Its line “CRA Services” maps to the standard task at 98%. As submitted: $10.90M for 1,313 visits at $8,301. Like-for-like: $17.20M for 1,967 visits at $8,744, Bluefen’s own rate card for full critical-data SDV — 20% over the $14.30M benchmark. Page 37 of the proposal sits beside it, the passage highlighted, with the monitoring plan’s visit frequency under it.
Bluefen, p. 37: “On-site monitoring visits are planned once every twelve (12) weeks per active site, with source data verification of 30% of CRF pages.”
- 05Next
Every gap, its effect and its severity
Assumption checkerSeventeen gaps in one list. Bluefen has nine worth +$11.95M — monitoring (+$6.30M), a 30-month study (+$0.78M), 1.0 query per patient visit (+$1.15M), 12 countries and 105 sites, 0.05 SAEs per patient, narratives excluded, ethics fees left “at cost”. Altamira has two: a 6% handling fee on pass-throughs in a footnote (+$1.05M) and translations left to the sponsor. Quillon’s 4.5% escalation from April 2027 is outside the 3% cap.
Exposure outside the total is flagged, not added: Quillon’s escalation is about $0.62M over the study, kept out of the like-for-like total and asked as a question.
- 06Drafted
One question per gap, each with its page
Clarification writerEleven questions, drafted per CRO, each citing the proposal page and the RFP line. To Bluefen: “Please re-price monitoring and CRA travel to the monitoring plan v1.2: on-site every 8 weeks while enrolling and 100% SDV of critical data — about 1,970 on-site visits.” Priya edits any question, then sends a CRO its set in one message.
A person sends every question, in a neutral tone — no competitor information is shared.
- 07Oct 7, 08:40
Altamira answers, and the grid moves
Priya Raman · Clinical outsourcing leadAltamira replies to question A1: it waives the handling fee for NXL-301, pass-throughs at cost, footnote 3 withdrawn. Priya applies the answer to the grid. Altamira’s like-for-like total drops from $54.92M to $53.87M, and the answer stays cited to Altamira’s response letter.
- 08Oct 3–6
A weighted scorecard on like-for-like price
The panelTechnical approach 40%, price like-for-like 30%, quality and oversight 20%, project team 10%. Five panel members — study lead, clinical operations, clinical QA, R&D finance and outsourcing — entered their scores. Altamira leads at 90.4 of 100. Altamira and Harborline go to the Oct 14 bid defence, with a brief drafted for the panel.
On submitted totals Bluefen would take the full price score; like-for-like it scores 4.74 of 5.
- 09Drafted
The award memo, every statement cited
Award memo writerSix sections from the scorecard, the grid and the gaps: the recommendation — Altamira Trials at $53.87M like-for-like — how the bids were compared, the like-for-like price table, the assumption gaps, quality and oversight, and the conditions. Translations priced against the $540K estimate, escalation capped at 3% a year, and the named project and CRA leads confirmed at bid defence. Eight citations checked.
- 10Signed · approved
Signed by the lead, approved under delegation of authority
Priya Raman · Omar HaddadPriya signs the recommendation with her password and the meaning of the signature, “I recommend this award”. Above $10M the award goes to Omar Haddad, head of clinical sourcing, who approves it subject to the Oct 14 bid defence. A work order request is drafted in the contract system, released once the panel confirms the named team, and the memo and grid are filed to the TMF under vendor selection.
“Electronic signature — name, date, time and meaning are recorded in the audit trail.”